Principia Biopharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 25, 2018
Founded by Jack Taunton's laboratory at UCSF in 2012, Principia Biopharma began trading in September at a generous $17.00 per share for its initial public offering (IPO) on the Nasdaq, raising approximately $122.2 million.

Principia Biopharma, a UCSF Spinout, Seeks $86 Million IPO - Bay Area's 11th Life Sciences IPO This Year

August 22, 2018
A South San Francisco company — one of a handful trying to block an enzyme implicated in a number of diseases — filed to raise $86.2 million in an initial public offering.

ZeClinics and the University of California, San Francisco (UCSF) Join Forces Against Epilepsy

July 23, 2018
ZeClinics SL, a leading zebrafish preclinical CRO, announced today that it has signed a licensing agreement with the Office of Technology Management, now within UCSF Innovation Ventures, which leads licensing and business development efforts on behalf of the university for the commercialization of...

Research Breakthrough: Parker Institute for Cancer Immunotherapy (PICI) Scientists at UCSF and UCLA Have Published a Nature Paper on Non-viral Genome Editing in T-cells Using CRISPR

July 11, 2018
Using CRISPR, PICI scientists create faster, more precise way of engineering cancer-fighting T cells – without the use of expensive viruses

Startup Science: How the Idea for Synthetic Cells Took Silicon Valley By Storm

June 13, 2018
Scientists working on the molecular and cellular level know that big things happen in small systems.

Akili (a UCSF Startup) Digital Medicine Technology Platform Granted Multiple Patents

April 10, 2018
New Patents Issued in U.S. and Japan Broadly Cover Unique Digital Mechanism for Assessing and Improving Cognitive Function Platform Technology Forms Foundation of Digital Medicine in Development to Treat Pediatric Attention-Deficit/Hyperactivity Disorder and Multiple Other Product Candidates

Roche Acquires Inception 5 Multiple Sclerosis (MS) Program Built on Discoveries by Dr. Jonah Chan at UCSF, Versant Forms New Company

April 05, 2018
Building on a four-year-old relationship Roche struck a deal to acquire a regenerative therapy program for multiple sclerosis from Inception Sciences a drug discovery engine co-founded with Versant Ventures in 2011.